JAB-21822

· Allist Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for JAB-21822, covering 2025-04-04 to 2026-03-16. Get the full timeline:

Most recent: Clinical Trial Update: JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation [Phase 1, Phase 2]

See pricing